摘要
目的本研究旨在对α-平滑肌肌动蛋白(α-SMA)及基质金属蛋白酶抑制剂(TIMP)在宫颈癌患者中的表达及临床意义分析,为临床诊断与治疗提供参考。方法对120例宫颈癌患者的临床资料进行回顾性研究,分析α-SMA及TIMP1和TIMP2在不同临床分期及预后的患者中表达情况。以本院100例同期健康体检者设为对照组。结果随着宫颈癌患者临床分级增高α-SMA及TIMP1和TIMP2表达逐步增强,且不同分级之间具有统计学差异性(P﹤0.05);在相同临床分期患者中,α-SMA及TIMP1和TIMP2与患者预后有关。结论α-SMA及TIMP1和TIMP2蛋白表达与宫颈癌患者临床分期及预后密切相关,可作为临床诊断宫颈癌和患者预后判断的重要标志物。
Objective To investigate the expression level and clinical significance ofα-SMA, TIMP1 and TIMP2 in cervical cancer patients, and discuss the role of them in diagnosis and treatment. Method 120 cases of cervical cancer patients were retrospectively analyzed, and the expression ofα-smooth muscle action （α-SMA） and tissue inhibitor of me-talloproteinase （TIMP1） and TIMP2 in patients with different clinical stage and prognosis were compared. In the same pe-riod, another 100 normal healthy adults were included as control. Result The expression ofα-SMA and TIMP1 as well as TIMP2 were increased as the clinical stage escalated, with significant differences observed between different clinical stages （P〈0.05）;For patients with same clinical stage, the expression ofα-SMA and TIMP1/2 were negatively associated with patients’prognosis. Conclusion The expression ofα-SMA and TIMP1, TIMP2 are markedly associated with the clinical stage and prognosis of cervical cancer, and may be utilized as predictors for diagnosis and prognosis of cervical cancer patients.
出处
《癌症进展》
2016年第7期651-653,共3页
Oncology Progress
